Edgewise Therapeutics
Quarterly Financials
| Values in thousands | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
|---|---|---|---|---|
| Revenue | $0 | $2,252 | $0 | $0 |
| Gross Profit | -525 | 1,719 | -448 | -437 |
| EBITDA | -34,228 | -33,329 | -29,452 | -24,878 |
| EBIT | -34,753 | -33,862 | -29,949 | -25,339 |
| Net Income | -28,525 | -30,143 | -25,713 | -21,469 |
| Net Change In Cash | 0 | 2,252 | 0 | 0 |
| Cost of Revenue | -16,423 | |||
| Free Cash Flow | -28,895 | -26,991 | -22,515 | -20,993 |
| Cash | 30,264 | 86,097 | 32,957 | 31,807 |
| Basic Shares | 87,567 | 64,774 | 63,459 | 63,380 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | -1,732 | -538 | -272 | -185 |
| EBITDA | -112,625 | -21,541 | -42,943 | -17,007 |
| EBIT | -114,357 | -22,079 | -43,215 | -17,192 |
| Net Income | -100,163 | -15,397 | -42,139 | -17,054 |
| Net Change In Cash | 0 | 0 | 0 | 0 |
| Cost of Revenue | 6,427 | -89,350 | ||
| Free Cash Flow | -97,693 | -58,181 | -34,175 | -14,837 |
| Cash | 86,097 | 351,947 | 280,789 | 104,916 |
| Basic Shares | 63,723 | 53,593 | 49,500 | 49,217 |
Earnings Calls
| Quarter | EPS |
|---|---|
| 2024-03-31 | -$0.33 |
| 2023-12-31 | -$0.47 |
| 2023-09-30 | -$0.41 |
| 2023-06-30 | -$0.34 |
